

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

**VOLUNTARY ANNOUNCEMENT
FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF
XUANZHU BIOPHARM'S ANAPRAZOLE SODIUM
FOR THE NEW INDICATION OF
HELICOBACTER PYLORI ERADICATION**

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the first patient has been successfully enrolled recently in the Phase III clinical study of Anaprazole Sodium Enteric-coated Tablets (trade name: An Jiu Wei), an innovative drug independently developed by Xuanzhu Biopharmaceutical Co., Ltd. (“**Xuanzhu Biopharm**”, stock code: 02575.HK), a non wholly-owned subsidiary of the Group, as part of a bismuth-containing quadruple therapy for the eradication of *Helicobacter pylori* (“**Hp**”), marking that this key registration clinical study has officially entered the substantive execution stage.

This Phase III clinical trial is a multi-centre, randomized, double-blind, double-dummy, active-drug parallel-controlled trial, which plans to enroll 556 adult subjects who are Hp positive. Using bismuth-containing quadruple therapy containing esomeprazole magnesium as the active control, the trial aims to evaluate the efficacy, safety and population pharmacokinetic characteristics of bismuth-containing quadruple therapy containing anaprazole sodium administered continuously for 14 days for Hp eradication. The primary endpoint is Hp eradication rate confirmed by ¹³C-urea breath test (“**¹³C-UBT**”) on day 28 after the completion of treatment.

Hp is a Gram-negative microaerophilic pathogenic bacterium closely associated with a variety of gastric diseases, including gastric ulcer, chronic progressive gastritis and gastric cancer. According to Frost & Sullivan, the infection rate of Hp in China is approximately 44%, and the market size of drugs for the treatment of Hp infection continues to expand. The market size in China reached RMB5.5 billion in 2024, and is projected to increase to RMB6.8 billion in 2029 and reach RMB12.6 billion in 2035.

Following the approval to initiate the Phase III clinical trial for Hp eradication indication by the Center for Drug Evaluation (“CDE”) of the National Medical Products Administration (“NMPA”) of the People’s Republic of China (“China”) in April 2026, the first patient was enrolled rapidly, which fully demonstrates the efficient execution capability of Xuanzhu Biopharm’s clinical development team and marks that the project has officially entered the key stage of clinical implementation. If this indication is successfully approved for marketing in the future, it is expected to further expand the target patient population of anaprazole sodium, accelerate the product’s market penetration, and create a new performance growth driver for the Company and Xuanzhu Biopharm in the digestive field.

ABOUT ANAPRAZOLE SODIUM ENTERIC-COATED TABLETS

Anaprazole Sodium Enteric-coated Tablets (trade name: An Jiu Wei) was approved for marketing by NMPA in June 2023 for the treatment of patients with duodenal ulcer. Anaprazole Sodium features an innovative structural design with characteristics including non-enzymatic plus multi-enzymatic metabolism and balanced intestinal-renal dual-channel excretion, with only 3.5% metabolized through CYP2C19, making it unaffected by CYP2C19 gene polymorphism. Compared with previous generations of proton pump inhibitors, Anaprazole Sodium has lower risk of drug-drug interactions, making it a safer choice for patients on multiple medications and those with renal impairment, and is a proton pump inhibitor more suitable for the Chinese population. As a Class 1 innovative drug in China, Anaprazole Sodium fills the gap in domestically developed proton pump inhibitors, bringing treatment options with both superior efficacy and safety to Chinese patients.

ABOUT XUANZHU BIOPHARM

Xuanzhu Biopharm was listed on the Main Board of the Stock Exchange of Hong Kong Limited in 2025 (stock code: 02575.HK). It is an innovative pharmaceutical company rooted in China with a global perspective, focusing on major diseases such as digestion, oncology and non-alcoholic steatohepatitis, and is committed to the research and development (“R&D”), production and commercialization of class 1 innovative drugs with core proprietary intellectual property rights. The company has a first-class R&D team that all core personnel have years of experience in new drug R&D. The company has two R&D platforms: small molecule chemistry and large molecule biopharmaceuticals. The dual engines drive the company’s innovation and development, forming a product pipeline that covers small molecule chemistry, large molecule biopharmaceuticals, antibody-drug conjugate (ADC) and other types of products. With a focus on unmet major clinical needs, the company is committed to developing into a first class innovative pharmaceutical company with independent R&D, production, and sales capabilities.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of the Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group’s latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 22 June 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.